Treatment Trials

4 Clinical Trials for Various Conditions

Focus your search

      AVAILABLE
      Expanded Access to Ensartinib for Participants With ALK+ NSCLC
      Description

      This is an open-label, multicenter, intermediate-sized expanded access treatment protocol to the existing IND 111,695 for ensartinib (X-396). The treatment plan is designed to provide ensartinib to participants with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).

      Conditions
      Non-Small Cell Lung CancerALK Gene Rearrangement Positive
      Talk to us
      TERMINATED
      A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
      Description

      This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.

      Conditions
      NeoplasmsColorectal NeoplasmsMelanomaPancreatic NeoplasmsSarcomaOvarian NeoplasmsBrain NeoplasmsThyroid NeoplasmsNeuroendocrine TumorsCholangiocarcinomaSalivary Gland NeoplasmsHead and Neck NeoplasmsThyroid Cancer, PapillaryLymphoma, Large-Cell, AnaplasticNeoplasms by SiteRespiratory Tract NeoplasmsThoracic NeoplasmsRespiratory Tract DiseasesCarcinoma, BronchogenicBronchial NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesCentral Nervous System
      Talk to us
      ACTIVE_NOT_RECRUITING
      Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer
      Description

      This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung cancer. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

      Conditions
      ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmROS1 Gene RearrangementStage IIIB Lung Non-Small Cell Cancer AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7
      Talk to us
      RECRUITING
      Study of SGR-1505 in Mature B-Cell Neoplasms
      Description

      The purpose of this study is to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and/or recommended dose (RD) of SGR-1505.

      Conditions
      Mature B-Cell NeoplasmNon Hodgkin LymphomaDLBCLWaldenstrom MacroglobulinemiaMALT LymphomaFollicular LymphomaPediatric-Type Follicular LymphomaIRF4 Gene RearrangementEBV-Positive DLBCL, NosBurkitt LymphomaPlasmablastic LymphomaHigh-grade B-cell LymphomaPrimary Cutaneous Follicle Center LymphomaPrimary Effusion LymphomaMantle Cell LymphomaDLBCL Germinal Center B-Cell TypePrimary Mediastinal Large B Cell LymphomaT-Cell/Histiocyte Rich LymphomaALK-Positive Large B-Cell LymphomaPrimary Cutaneous Diffuse Large B-Cell LymphomaSplenic Marginal Zone LymphomaChronic Lymphocytic LeukemiaNodal Marginal Zone LymphomaHHV8-Positive DLBCL, NosLymphoplasmacytic LymphomaDuodenal-Type Follicular Lymphoma
      Talk to us